Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733710 | 0.90 | HSD11B1 (0.57) | HSD11B1L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL7442356 | 0.86 | L3MBTL1 (0.49) | L3MBTL1MEN1KMT2AALDH1A1ACE | |
| SCHEMBL4522790 | 0.86 | L3MBTL1 (0.43) | HSD11B1L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL2946980 | 0.83 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1 | |
| SCHEMBL5758709 | 0.83 | L3MBTL1 (0.51) | L3MBTL1MEN1KMT2AALDH1A1DDB1 | |
| SCHEMBL14177598 | 0.82 | HSD11B1 (0.53) | HSD11B1L3MBTL1MEN1KMT2AACHE | |
| SCHEMBL6734403 | 0.79 | HSD11B1 (0.56) | HSD11B1KMT2AALDH1A1DDB1CRBN | |
| SCHEMBL6202280 | 0.79 | L3MBTL1 (0.51) | L3MBTL1MEN1KMT2AALDH1A1DDB1 | |
| SCHEMBL22450145 | 0.79 | HSD11B1 (0.56) | HSD11B1KMT2AALDH1A1CCR3DDB1 | |
| SCHEMBL16874753 | 0.79 | L3MBTL1 (0.51) | HSD11B1L3MBTL1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6680331-B2 | ADMINISTERING DIETHYL LACTAMS SUCH AS 3,3-DIETHYL-2-PYRROLIDINONE FOR INDUCING ANESTHESIA OR CONSCIOUS SEDATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-01-20 | — | — | US | disclosed |
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-04-24 | — | — | US | disclosed |
| US-6329392-B1 | ANTIALLERGENS | AVENTIS PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| CN-1067385-C | Novel substituted piperidines useful for the treatment of allergic diseases | MERRELL DOW PHARMA (US) | 2001-06-20 | — | — | CN | disclosed |
| US-6066666-A | OPTIONALLY N-SUBSTITUTED 3-MONO- AND DI-SUBSTITUTED 2-PYRROLIDINONES AND THIOLACTAM ANALOGS; TREAT SEIZURES, ANXIETY, AND ENHANCING 4-AMINOBUTYRIC ACID (GABA)-INDUCED CHLORIDE CURRENTS AT GABA RECEPTOR/IONOPHORE COMPLEX | WASHINGTON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| EP-0777666-B1 | SUBSTITUTED PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | MERRELL PHARMA INC (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5776959-A | Anticonvulsant and anxiolytic lactam and thiolactam derivatives | WASHINGTON UNIVERSITY (US) | 1998-07-07 | — | — | US | disclosed |
| CN-1158612-A | Novel substituted piperidines for the treatment of allergic diseases | MERRELL DOW PHARMA (US) | 1997-09-03 | — | — | CN | disclosed |
| EP-0777666-A1 | NOVEL SUBSTITUTED PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | MERRELL PHARMACEUTICALS INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996006094-A1 | NOVEL SUBSTITUTED PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | MERRELL PHARMACEUTICALS INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | GABRD, GABRE, CCT8 | HSD11B1 3696/4885L3MBTL1 1118/4885MEN1 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.